BECTON DICKINSON HITS 10% REVENUE GROWTH TARGET IN THREE CORE BUSINESSES DURING FISCAL 1996, FIRM TELLS ANALYSTS; 15% EARNINGS INCREASE FORECAST FOR FISCAL 1997
This article was originally published in The Gray Sheet
Three of Becton Dickinson's six core businesses posted fiscal 1996 revenue growth at or above the firm's targeted 10% rate, Vincent De Caprio, BD's senior VP and chief technology officer, told analysts Nov. 19 in New York City.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.